Chiglitazar Sodium Ingredient API Active Pharmaceutical Antidiabetic Functi

Chiglitazar Sodium is a new molecular entity developed by Wanggo Biotechnology
Co., LTD. It is a peroxisome proliferator activated receptor (PPAR) complete
agonist that can simultaneously activate three subtypes of PPAR receptors (α,
γ and δ). Chiglitazar Sodium is a Chinese chemical drug class. Approved for
marketing by NMPA on October 19, 2021, single drug is suitable for improving
glycemic control in adult patients with type 2 diabetes in combination with
diet control and exercise .

Type 2 diabetes, formerly known as non-insulin-dependent diabetes mellitus or
adult-onset diabetes mellitus, is a chronic metabolic disease, mostly occurring
after the age of 35 to 40, and the incidence is increasing. The common symptoms
are polyuria, polydipsia, polyophagia and weight loss. The main causes of type
2 diabetes include heredity, environment and lifestyle . The striking
pathophysiological features are a reduction in insulin's ability to regulate
glucose metabolism (insulin resistance) and a reduction in insulin secretion
(relative reduction) due to impaired islet beta cell function. The prevalence
of diabetes in China is mainly type 2 diabetes, accounting for more than 90% of
the diabetes population, type 1 diabetes and other types of diabetes are rare.
The incidence of diabetes is higher in males than in females, and in urban
areas than in rural areas. The proportion of undiagnosed diabetes is higher,
and the prevalence of diabetes in obese and overweight people increases
significantly .



The approval of Chiglitazar Sodium is based on the results of two phase III
trials of 525 patients with type 2 diabetes using placebo and 740 patients
using sitagliptin, respectively. Sitagliptin significantly reduced HbA1c levels
at 24 weeks, by 1.52% at 52 weeks. In terms of secondary efficacy measures,
sitaglitastatin showed a long-term and sustained reduction in fasting glucose
and 2 h postprandial glucose, with no secondary failure observed at 52 weeks.
Two experiments of Chinese and western of sodium Glenn he showed significant
hypoglycemic effect and good security for a long time, west Glenn he sodium in
improving the insulin resistance, protection of beta islet cell function and
regulate blood fat also shows a good potential of comprehensive prevention and
treatment of type 2 diabetes mellitus and complications, can provide patients
with better treatment effect, safety, Significantly improved the quality of
life of patients .

Click to Enlarge